Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
about
Use of Reporter Genes in the Generation of Vaccinia Virus-Derived VectorsRecombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes.Inoculation of Plasmids Encoding Japanese Encephalitis Virus PrM-E Proteins with Colloidal Gold Elicits a Protective Immune Response in BALB/c MiceOvercoming immunity to a viral vaccine by DNA priming before vector boostingPre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverInduction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells.Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectorsPrior immunity to homologous and heterologous Salmonella serotypes suppresses local and systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with Salmonella strains expressing fragment CImmediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responsesVaccinia virus vectors: new strategies for producing recombinant vaccines.Current approaches to vaccine preparation.Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 proteinPreexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccineHumoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military PopulationsReplication-incompetent herpesvirus vector delivery of an interferon alpha gene inhibits human immunodeficiency virus replication in human monocytes.Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunityReplication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection.Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activityProtection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.Transgenic mouse lines that are immunologically tolerant and nontolerant to herpes simplex virus glycoprotein DExpression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals.Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice.Human cytotoxic T-cell memory: long-lived responses to vaccinia virus.Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity.Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen.Lack of immunodominance in the T cell response to herpes simplex virus glycoprotein D after administration of infectious virus.Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.
P2860
Q26746915-84B4E84A-1E96-4048-ADC1-DE2F242F68CBQ27469314-55908356-50E3-4AAA-A8DF-D97EC6CABBE2Q27469568-6635B858-01AF-4FCC-821D-60E6B3798818Q27473373-2256817B-C060-42BF-81E0-F5907EFDC74BQ28217213-50DD2524-F28A-4D36-9C36-DFAD71883A50Q28740522-112C4D39-B010-4878-A6BD-9D27812590B3Q33471448-64F1A533-92F2-4DA7-AEEF-EB20C34E1FF6Q33684465-6F187CA7-E14B-47D2-936C-410157C6CCC5Q33835258-B8A97A37-337C-4B04-BDC0-B8A3262E2A76Q34001326-EBDC1194-D98A-424C-BBDC-4F83AAC77A29Q34055541-3CFE1788-579C-46D3-AD43-DE5C668B41D8Q34211635-CF1842A7-31D7-4929-924E-9578D725CB08Q34688016-C06EC960-3CBB-47C0-AE34-207D615DFF6DQ35130248-7C7F9C6A-EE80-41E4-B78A-8E98B605E265Q35868054-09CF734C-C6AE-4CE9-8F35-A100A15E1BBEQ35946213-860E9991-4DD3-4DE3-9B3A-C0BA9B25DD2EQ36091993-05DF6ACC-5E82-46FC-8079-1D28681FCCB9Q36137980-B39CE064-D3B0-4F37-BF07-5F9C0555E28EQ36141586-4B18D0DE-CD67-4553-BF37-63FFD911AC06Q36238314-CD22050B-3A28-482B-937D-3FDAA8945408Q36574880-F4FEE42D-EC85-44AE-95E0-00909FCDC8E4Q36626882-6819A36F-7CEE-40DC-8852-D8099539E61AQ36679394-E6F3F185-0610-4594-9102-4F3B4358ACCBQ36686845-306FB8C4-9AE9-4F4A-B8C2-DDAC908B59F8Q36782189-6120EBDA-ADB2-4A0B-BB31-9ED0C1C160F1Q36799854-746FE97E-1BA9-4F6C-90AD-E954B49B4ECBQ36821526-557B7C18-4555-486E-9197-775BA4615CAEQ36830970-191DE0B1-AEEA-46B8-A88C-640541C2164EQ39592790-AEF86B63-B7BA-4BF0-82E2-B1220141514DQ39864202-14D9AE1B-9C65-46D8-86C3-3D9C46A0F2B7Q39874178-6C080417-B0A2-4EE0-A6DA-D27B743FBCA3Q40108953-BF792A3D-E515-4D51-ABAC-CDDD5CAD6374Q40375560-A3C68D21-3BF4-459B-ACFA-C3A81CFF3ED3Q42939767-DBDB1D2A-2BDE-4E38-9C20-3DF868A7FC51Q55114818-03FD258C-0D43-4B73-8C0E-4F1C24AF3ECC
P2860
Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Immunization with a vaccinia v ...... n and effect of revaccination.
@en
type
label
Immunization with a vaccinia v ...... n and effect of revaccination.
@en
prefLabel
Immunization with a vaccinia v ...... n and effect of revaccination.
@en
P2093
P2860
P1433
P1476
Immunization with a vaccinia v ...... n and effect of revaccination.
@en
P2093
P2860
P304
P407
P577
1988-05-01T00:00:00Z